Neoplasms

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Lymphoma

Lymphoma, B-Cell, Marginal Zone

Lymphoma, B-Cell

Neoplasms by Histologic Type

Lymphoproliferative Disorders

Lymphatic Diseases

Immunoproliferative Disorders

Lymphoma, Non-Hodgkin

Lymphosarcoma

B-cell Lymphoma

Marginal Zone Lymphoma

Gastric Lymphoma

Anti-Infective Agents

All Drugs and Chemicals

Gastrointestinal Agents

Metronidazole

Amoxicillin

Anti-Bacterial Agents

Bismuth

Antibiotics, Antitubercular

Clarithromycin

Omeprazole

Tetracycline

Antacids

Bismuth subsalicylate

Anti-Ulcer Agents

Antiprotozoal Agents

Antiparasitic Agents

Proton Pump Inhibitors

Enzyme Inhibitors

Cytochrome P-450 CYP3A Inhibitors

Cytochrome P-450 Enzyme Inhibitors

Loperamide

Antidiarrheals

Bismuth Subsalicylate

Metronidazole Hydrochloride

Tetracycline Hydrochloride

Gideon Steinbach, MD, PhD

RATIONALE: Antibiotic therapy and antacids are used to treat Helicobacter pylori infection of the stomach. These treatments may also have an effect on gastric MALT lymphoma of the stomach.

PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy with amoxicillin, clarithromycin, tetracycline, and metronidazole plus antacids in patients with MALT lymphoma of the stomach.

OBJECTIVES: I. Evaluate the response of gastric lymphoma of mucosa-associated lymphoid tissue (MALT) to treatment for Helicobacter pylori infection with antibiotics (amoxicillin, clarithromycin, tetracycline, and metronidazole) and with gastric acid inhibitors (omeprazole and bismuth subsalicylate). II. Correlate response with endoscopic tumor grade and clinical and pathological parameters. III. Assess the incidence of H. pylori infection in patients with gastric MALT lymphoma.

OUTLINE: All patients are treated on Regimen A; those receiving tetracycline on Regimen A are switched to Regimen B for their second course; those receiving amoxicillin for their first course receive tetracycline for their second course. Regimen A: Antibiotic Therapy with Gastric Acid Inhibition. Amoxicillin (or Tetracycline in penicillin-allergic patients); Clarithromycin; with Bismuth Subsalicylate; Omeprazole. Regimen B: Antibiotic Therapy with Gastric Acid Inhibition. Tetracycline; Metronidazole, METRO, NSC-50364; with Bismuth Subsalicylate; Omeprazole.

PROJECTED ACCRUAL: 75 patients will be entered over 3 years.

Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach

CURRENT PRACTICE STUDY OF ANTIBIOTIC TREATMENT OF GASTRIC MALT LYMPHOMA

National Cancer Institute (NCI)

M.D. Anderson Cancer Center

Symptoms and General Pathology

Leukemia, Lymphocytic, Chronic, B-Cell

Chronic Lymphocytic Leukemia

Bismuth tripotassium dicitrate

bismuth subcitrate

amoxicillin

clarithromycin

metronidazole hydrochloride

omeprazole

tetracycline hydrochloride

Patrice P. Carde, MD

John W. Sweetenham, MD

RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma.

PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric lymphoma that has not been previously treated.

OBJECTIVES: I. Determine the rate of eradication of Helicobacter pylori using omeprazole, colloidal bismuth subcitrate, tetracycline, and metronidazole in patients with low grade gastric lymphoma. II. Determine the macroscopic/endoscopic and microscopic healing/remission rate after eradication of Helicobacter pylori in this patient population. III. Determine the natural history of low grade gastric lymphoma after eradication of Helicobacter pylori.

OUTLINE: This is a nonrandomized, open label, multicenter study. Patients receive oral omeprazole bid on days 1-10, oral bismuth subcitrate and oral tetracycline qid on days 4-10, and oral metronidazole tid on days 4-10. Patients are evaluated at 8 weeks. Patients who experience complete remission and are H. pylori negative proceed to follow up. Patients with complete remission or no change but who are H. pylori positive proceed to a second course of therapy with the previous schedule or with omeprazole bid, amoxicillin qid, and clarithromycin tid for 14 days. Patients who experience no change but are H. pylori negative are followed at 6 and 9 months and restaged. Patients are followed at 6, 9, 12, 18, and 24 months, then annually thereafter.

PROJECTED ACCRUAL: Approximately 60-96 patients will be accrued for this study.

Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma

A Phase II Clinical Trial of Anti-Helicobacter Pylori Treatment in Endoscopically Diagnosed Low-Grade Localized Gastric Lymphoma

University of Glasgow

European Organisation for Research and Treatment of Cancer - EORTC

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach	NCT00002682	Lymphoma	Amoxicillin Bismuth Subsali... Clarithromycin Metronidazole H... Omeprazole Tetracycline Hy...	18 Years - 80 Years	M.D. Anderson Cancer Center
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma	NCT00003151	Lymphoma	bismuth subcitr... amoxicillin clarithromycin metronidazole h... omeprazole tetracycline hy...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma	NCT00003151	Lymphoma	bismuth subcitr... amoxicillin clarithromycin metronidazole h... omeprazole tetracycline hy...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC

Spots Global Cancer Trial Database for metronidazole hydrochloride